[{"orgOrder":0,"company":"AOP Orphan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AOP Orphan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AOP Orphan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AOP Orphan \/ Inapplicable"},{"orgOrder":0,"company":"AOP Orphan","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Landiolol Hydrochloride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AOP Orphan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AOP Orphan \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AOP Orphan \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"AOP Orphan","sponsor":"ANOVA CRO | PharmaLex | Aixial s.r.o. | GCP-Service International","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"AOP Orphan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AOP Orphan \/ ANOVA CRO | PharmaLex | Aixial s.r.o. | GCP-Service International","highestDevelopmentStatusID":"11","companyTruncated":"AOP Orphan \/ ANOVA CRO | PharmaLex | Aixial s.r.o. | GCP-Service International"},{"orgOrder":0,"company":"AOP Orphan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Hematology","graph2":"Phase III","graph3":"AOP Orphan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AOP Orphan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AOP Orphan \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by AOP Orphan

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : BESREMi

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 23, 2024

                          Lead Product(s) : Ropeginterferon-Alfa-2b

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 05, 2024

                          Lead Product(s) : Treprostinil Sodium

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 19, 2024

                          Lead Product(s) : Treprostinil Sodium

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : ANOVA CRO | PharmaLex | Aixial s.r.o. | GCP-Service International

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : The Company will support the submission of a new drug application to the U.S. FDA seeking approval for Landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flut...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : $5.0 million

                          September 08, 2021

                          Lead Product(s) : Landiolol Hydrochloride

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Eagle Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 28, 2016

                          Lead Product(s) : AOP2014

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Fondazione Ricerca Ospedale di Bergamo

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 14, 2015

                          Lead Product(s) : Pegylated-Proline-Interferon alpha-2b

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : PharmaEssentia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 15, 2014

                          Lead Product(s) : Pegproline Interferon Alfa-2b

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : PharmaEssentia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 04, 2014

                          Lead Product(s) : Anagrelide Hydrochloride

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          September 25, 2013

                          Lead Product(s) : Interferon Alfa-2B

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : PharmaEssentia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 02, 2013

                          Lead Product(s) : Ropeginterferon-Alfa-2b

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Arbeitsgemeinschaft medikamentöse Tumortherapie

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank